University of California San Francisco
Give to UCSF
A newly approved drug that is the first to reflect the current scientific understanding of multiple sclerosis is holding new hope for the hundreds of thousands Americans living with the disease. It also highlights the importance of clinician scientists like UCSF’s Stephen Hauser who are working to transform research into cures for patients.
Neuroimaging is helping to distinguish between depression and dementia – two diseases with overlapping symptoms that can be difficult to diagnose properly.
Studying brain disorders is complicated for many reasons, not the least being the ethics of obtaining living neurons. To overcome that obstacle, UCSF postdoc Aditi Deshpande is starting with skin cells.
Sharks, rays and skates can hunt for prey hidden in the sandy sea floor by “listening” for faint traces of bioelectricity – they can literally sense their prey’s heart beating.
In an unprecedented leap from lab to patients, a potential treatment for childhood epilepsy identified in experiments with zebrafish.
New research is paving the way to a precision medicine approach to the diagnosis and treatment of patients with traumatic brain injury.
Research uses brain “organoids” — tiny 3D models of human organs that scientists grow in a dish to study disease — to identify root causes of MDS, a rare genetic disorder that causes fatal brain malformations.
Poor performance on a simple odor identification test was associated with a significantly increased risk of developing dementia years later.
Distinct sets of genetic defects in a single neuronal protein can lead either to infantile epilepsy or to autism spectrum disorders.
A common treatment for irregular heartbeats known as catheter ablation may result in the formation of brain lesions when it is performed on the left side of the heart.
For concussion sufferers, physicians may now be able to predict early on who is more likely to continue experiencing symptoms months or years after the head-jarring event.
UC San Francisco and Pfizer Inc.’s Centers for Therapeutic Innovation have renewed an agreement to identify and develop biologic compounds against both known and novel targets.
Researchers at UCSF have developed a new optogenetic tool that can be used to completely eliminate single cells from brain networks in animals. The researchers believe the new tool will enable exquisitely precise experiments to help researchers understand how each cell contributes to the whole.
In findings that show the effectiveness of a new strategy for treating multiple sclerosis, researchers are reporting positive results from three large, international, multicenter Phase III clinical trials of the investigational drug ocrelizumab in both relapsing multiple sclerosis and primary progressive multiple sclerosis.
